ସୁକ୍ରାଲଫେଟ

ସୁକ୍ରାଲଫେଟ
Clinical data
Trade names	Carafate
AHFS/Drugs.com	monograph
MedlinePlus	a681049
data	US DailyMed: Sucralfate;
Pregnancy; category	B;
Routes of; administration	By mouth, rectal
Legal status
Legal status	US: ℞-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	3-5% (local acting)
Metabolism	GI; liver: unknown
Elimination half-life	unknown
Excretion	Feces, urine
Identifiers
	IUPAC name Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum;
ECHA InfoCard	100.053.636
Chemical and physical data
Formula	C12H54Al16O75S8
Molar mass	୨,୦୮୬.୬୭ g·mol−1
(verify)

ସୁକ୍ରାଲଫେଟ ଏକ ଔଷଧ ଯାହା ବିଭିନ୍ନ ବ୍ରାଣ୍ଡ ନାମରେ ବିକ୍ରି ହୁଏ ଓ ପାକସ୍ଥଳୀ ଘାଆ, ଗ୍ୟାଷ୍ଟ୍ରୋସୋଫେଜାଲ୍ ରିଫ୍ଲକ୍ସ ରୋଗ (GERD), ବିକିରଣ ପ୍ରୋକ୍ଟାଇଟିସ ଓ ପାକସ୍ଥଳୀ ପ୍ରଦାହ ଭଳି ରୋଗମାନଙ୍କ ଚିକିତ୍ସାରେ ବ୍ୟବ‌ହୃତ ହୁଏ ଏବଂ ଚାପ‌ଯୁକ୍ତ ଘାଆର ପ୍ରତିଷେଧ ଭାବରେ ଦିଆଯାଏ | ^[୨] ^[୩] ^[୪] ଏଚ ପାଇଲୋରି (H. pylori ) ସଂକ୍ରମିତ ଲୋକଙ୍କ କ୍ଷେତ୍ରରେ ଏହାର ଉପଯୋଗୀତା ସୀମିତ ଅଟେ | ^[୫] ଏହା ପାଟିରେ କିମ୍ବା ମଳଦ୍ୱାର ବାଟେ ଦିଆଯାଏ | ^[୫] ^[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କୋଷ୍ଠକାଠିନ୍ୟ ହୋଇପାରେ | ^[୫] ଗମ୍ଭୀର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ପିଣ୍ଡୁଳା ଗଠନ ଏବଂ ଏନସେଫାଲୋପାଥି ହୋଇପାରେ | ^[୭] ଗର୍ଭାବସ୍ଥା ଏବଂ ସ୍ତନ୍ୟପାନରେ ବ୍ୟବହାର କଲେ ନିରାପଦ ମନେହୁଏ | ^[୮] ଏହା କିପରି କାର୍ଯ୍ୟ କରେ ତାହା ଅସ୍ପଷ୍ଟ କିନ୍ତୁ ଅଲସରକୁ ବାନ୍ଧି ରଖିବା ଏବଂ ଅଧିକ କ୍ଷତିରୁ ସୁରକ୍ଷା କରେ ବୋଲି ବିଶ୍ୱାସ କରାଯାଏ | ^[୫] ^[୮]

ସୁକ୍ରାଲଫେଟ ୧୯୮୧ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ନିମନ୍ତେ ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୫] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ । ^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ $ ୦.୨୨ ଆମେରିକୀୟ ଡଲାର ଅଟେ । ^[୯] ୨୦୧୭ ରେ, ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୧୮ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ଦୁଇ ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା। ^[୧୦] ^[୧୧]

ଆଧାର

↑ Merck Index, 12th Edition, 9049.
↑ "Sucralfate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists.
↑ Maton PN (November 2003). "Profile and assessment of GERD pharmacotherapy". Cleveland Clinic Journal of Medicine. 70 Suppl 5: S51-70. doi:10.3949/ccjm.70.Suppl_5.S51. PMID 14705381.
↑ Mendenhall WM, McKibben BT, Hoppe BS, Nichols RC, Henderson RH, Mendenhall NP (October 2014). "Management of radiation proctitis". American Journal of Clinical Oncology. 37 (5): 517–23. doi:10.1097/COC.0b013e318271b1aa. PMID 23241500.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ "Sucralfate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists.
↑ Mendenhall WM, McKibben BT, Hoppe BS, Nichols RC, Henderson RH, Mendenhall NP (October 2014). "Management of radiation proctitis". American Journal of Clinical Oncology. 37 (5): 517–23. doi:10.1097/COC.0b013e318271b1aa. PMID 23241500. S2CID 12129192.
↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 73. ISBN 9780857113382.
↑ ^୮.୦ ^୮.୧ ^୮.୨ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 73. ISBN 9780857113382.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
↑ "Sucralfate - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[Merck-1] Merck Index, 12th Edition, 9049.

[AHFS2019-2] "Sucralfate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists.

[Mat2003-3] Maton PN (November 2003). "Profile and assessment of GERD pharmacotherapy". Cleveland Clinic Journal of Medicine. 70 Suppl 5: S51-70. doi:10.3949/ccjm.70.Suppl_5.S51. PMID 14705381.

[Brad2014-4] Mendenhall WM, McKibben BT, Hoppe BS, Nichols RC, Henderson RH, Mendenhall NP (October 2014). "Management of radiation proctitis". American Journal of Clinical Oncology. 37 (5): 517–23. doi:10.1097/COC.0b013e318271b1aa. PMID 23241500.

[autogen3-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ "Sucralfate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists.

[autogen1-6] Mendenhall WM, McKibben BT, Hoppe BS, Nichols RC, Henderson RH, Mendenhall NP (October 2014). "Management of radiation proctitis". American Journal of Clinical Oncology. 37 (5): 517–23. doi:10.1097/COC.0b013e318271b1aa. PMID 23241500. S2CID 12129192.

[BNF76-7] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 73. ISBN 9780857113382.

[autogen2-8] ୮.୦ ^୮.୧ ^୮.୨ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 73. ISBN 9780857113382.

[NADAC2019-9] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-10] "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.

[ref1-11] "Sucralfate - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[୨]

[୩]

[୪]

[୫]

[୬]

[୧]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]